There’s now a chance for bipartisan health care policies, but partisan tensions are running high

What's new in pharma

July 11, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Andrew Harnik/Getty Images STAT+ | There's now a chance for bipartisan health care policies, but partisan tensions are running high Pending health care issues — telehealth, PBM reform, Medicare doctor pay, Obamacare extensions — will require bipartisanship. A lot stands in the way. By John Wilkerson STAT+ | FDA rejects Capricor's cell therapy for Duchenne muscular dystrophy The company had submitted data from a study that yielded mixed results, the kind of case that can be a flashpoint for regulatory controversy. By Adam Feuerstein STAT+ | California stem cell agency shutting down unique human tissue biobank California Institute for Regenerative Medicine (CIRM) is closing its biobank, citing high costs and low usage By Jonathan Wosen Alex Hogan/STAT STAT+ | Up and down the ladder: The latest comings and goings From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry. By Ed Silverman

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser